Patents by Inventor Andrew Dahl
Andrew Dahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11806375Abstract: An algal biomass and supernatant derived from at least one species of algae exhibits the ability to maintain general health in humans and non-human animals and promote a healthy immune system in them. Food, feed and nutritional supplements comprising an algal biomass or supernatant derived from at least one species of algae are described. Methods of maintaining general health or promoting a healthy immune system in humans and non-human animals comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or homeopathic compound derived from the algae species, biomass or supernatant, or a composition thereof.Type: GrantFiled: February 15, 2017Date of Patent: November 7, 2023Assignee: Zivo Bioscience, Inc.Inventors: Andrew A. Dahl, Amy E. Steffek
-
Publication number: 20230338414Abstract: An effective treatment mechanism in controlling a variety of diseases by modulating the inflammatory response often associated with disease is disclosed. The disclosed inventive concept is based on the modulation of TLR4 by use of a member of the Variovorax group or the Rhodobacter group. Specifically, the Gram-negative bacterium Variovorax paradoxus or the Gram-negative bacterium Rhodobacter sphaeroides is used according to the disclosed inventive concept in the treatment of disease by reducing or inhibiting inflammatory responses.Type: ApplicationFiled: April 26, 2023Publication date: October 26, 2023Applicant: ZIVO Bioscience, Inc.Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
-
Publication number: 20230218681Abstract: An improved agent and treatment method for a broad variety of diseases in both animals and humans is disclosed. The agent is an inventive composition comprising a bacterial-based culture. Particularly, the inventive composition disclosed herein is an active molecule produced by a Gram-negative bacterial strain that is a member of the genus Brevundimonas. Consumption of the inventive composition by way of liquid or dry feed produces a broad range of health benefits and has proven effective in the prevention and treatment of disease. The bacterium of the disclosed composition selectively modulates Toll-like receptors (TLRs) for the prevention and treatment of disease such as coccidiosis. Specific actions include but are not limited to improvement of gut health, acceleration or enhancement of immune response using a natural immune modulator, and the promotion of animal growth.Type: ApplicationFiled: December 7, 2022Publication date: July 13, 2023Applicant: Zivo Bioscience, Inc.Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
-
Publication number: 20220240542Abstract: A method and compound for promoting growth and priming the immune system in both animals and humans are disclosed. The disclosed method utilizes a compound derived from one or more of a lipopolysaccharide, Lipid A, and fractions, derivatives, and cellular components thereof of gram-negative bacteria. The compound is combined with conventional feed, such as corn-soy feed, for administration to animals, such as poultry. Human application is possible, as well. Kinomic analysis of tissues collected from sacrificed birds fed the dietary mixture of the inventive compound and conventional feed suggests that the biomass causes an alteration of signaling in multiple growth-related pathways. These pathways include, but are not limited to, those associated with the vascular endothelial growth factor (VEGF), the mitogen-activated protein kinase (MAPK or MAP kinase), Ak strain transforming (Akt), and the neurotrophic tropomyosin-related kinase (NTRK).Type: ApplicationFiled: January 28, 2022Publication date: August 4, 2022Applicant: ZIVO Bioscience, Inc.Inventors: William P. Pfund, Amy E. Steffek, Andrew A. Dahl
-
Publication number: 20220233608Abstract: A method and compound for promoting growth in both animals and humans are disclosed. The disclosed method utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The compound itself is a natural product with no observed adverse environmental impact. The compound is combined with conventional feed, such as a corn-soy feed, for administration to animals, such as poultry. Human application is possible, as well. The combination of the disclosed inventive compound and conventional feed works through multiple growth-related pathways within, for example, in healthy birds to enhance growth performance while also priming the immune system to expedite response to a disease challenge should one arise. Data indicate that the dietary mixture of the inventive compound in conventional feed suggests that the biomass alters the signaling of multiple growth-related pathways.Type: ApplicationFiled: August 24, 2021Publication date: July 28, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Amy E. Steffek, Andrew A. Dahl, William P. Pfund
-
Publication number: 20220226398Abstract: A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed inventive compound and method of treatment find particular application in the treatment of disease in poultry, particularly in the prevention and treatment of coccidiosis.Type: ApplicationFiled: January 14, 2022Publication date: July 21, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
-
Publication number: 20220226394Abstract: A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The treatment compound and the use of such a compound such as that derived from a bacterium that appears to selectively alter one or more TLR pathways in the prevention and treatment of disease in both animals and humans. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed inventive compound and method of treatment find particular application in the treatment of disease in poultry, particularly in the prevention and treatment of coccidiosis.Type: ApplicationFiled: January 14, 2022Publication date: July 21, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
-
Publication number: 20220125859Abstract: An improved agent and treatment method for a broad variety of diseases in both animals and humans are disclosed. The agent is an inventive treatment compound comprising a bacterial-based culture. The inventive treatment compound has a positive impact on the gut health of boilers from the earliest stage onward. These benefits are realized through several mechanisms, including improved gut morphology under disease stress. Healthier gut morphology and improved gut integrity result in improved nutrient uptake and growth benefits, both based on consumption of the disclosed inventive treatment compound. The downstream results are improvements in performance parameters related to gut health including altering gut microbes, feed conversion rates, and body weight gains among others. Use of the disclosed treatment compound has the further benefit of avoiding contamination during animal processing because of the reduction in the volume of pathogenic bacteria in the gut.Type: ApplicationFiled: September 2, 2021Publication date: April 28, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Amy E. Steffek, William P. Pfund, Andrew A. Dahl
-
Publication number: 20220072074Abstract: An algal biomass used as a natural ingredient in poultry feed reverses the detrimental effects of coccidiosis and necrotic enteritis in poultry. Algal biomass augmented poultry feed was shown to improve feed conversion rates, reduce mortality rates, and reduce intestinal lesion scores. In various embodiments, the algal biomass comprises at least one species of Klebsormidium. In various aspects, the algal biomass may be obtaining by continuously cultivating at least one species of Klebsormidium in raceway ponds, separating the plant material and spray drying to obtain the algal biomass.Type: ApplicationFiled: December 19, 2019Publication date: March 10, 2022Applicant: Zivo Bioscience, Inc.Inventors: Andrew A. Dahl, Amy E. Steffek, William P. Pfund
-
Publication number: 20220062403Abstract: An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.Type: ApplicationFiled: July 2, 2021Publication date: March 3, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
-
Publication number: 20220053799Abstract: An effective treatment method and composition for controlling a variety of diseases including disease in poultry are disclosed. The inventive concept set forth herein provides an improved long-lasting treatment having a positive latency effect for a broad variety of diseases that is easy to administer and cost effective. The disclosed method of treatment utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. By administering the compound early in broiler life, disease prevention and treatment via immune modulation result. The treatment has a lasting effect throughout the entire broiler production period. The composition itself is a natural product and thus has no adverse environmental impact unlike known antibiotic regimens. By providing effective treatment during the stage of life where feed consumption is lowest by volume, costs to the producer are advantageously limited.Type: ApplicationFiled: June 25, 2021Publication date: February 24, 2022Applicant: ZIVO Bioscience, Inc.Inventors: William P. Pfund, Amy E. Steffek, Andrew A. Dahl
-
Publication number: 20220048958Abstract: Compounds capable of selectively modulating the TLR signaling pathway provide an improved treatment method for a broad variety of diseases in both animals and humans. The mechanisms of action in the treatment and/or prevention of coccidiosis and other conditions related to gut inflammation are via a direct effect on innate and adaptive immune pathways. The downstream results are improvements in performance parameters related to gut health (including altering gut microbes, conversion rates, and body weight gains among others. When administered to animals, the bioactives of the disclosed inventive compound mitigate the effects of coccidiosis via an enhanced immune response rather than a direct effect on parasites, such as the Eimeria parasite. The mechanisms of action of the disclosed inventive compound and method are via immune system priming rather than a direct effect on pathogens, thus there is no risk of treatment resistance being developed.Type: ApplicationFiled: August 12, 2021Publication date: February 17, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
-
Publication number: 20220016240Abstract: A method and compound for altering the status of both innate and adaptive immune pathways in both animals and humans are disclosed. The status alteration results in the immune response being primed whereby an accelerated and more robust response is generated when the animal or human is challenged by pathogens that lead to a wide range of disease states. The disclosed method utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The compound itself is a natural product with no observed adverse environmental impact. By priming the immune pathways according to the disclosed inventive concept, the severity of various disease states can be reduced, can be resolved more quickly, or can be avoided entirely.Type: ApplicationFiled: June 25, 2021Publication date: January 20, 2022Applicant: ZIVO Bioscience, Inc.Inventors: Amy E. Steffek, Andrew A. Dahl, William P. Pfund
-
Publication number: 20210353732Abstract: An effective treatment mechanism in controlling a variety of diseases by modulating the inflammatory response often associated with disease is disclosed. The disclosed inventive concept is based on the modulation of TLR4 by use of a member of the Variovorax group or the Rhodobacter group. Specifically, the Gram-negative bacterium Variovorax paradoxus or the Gram-negative bacterium Rhodobacter sphaeroides is used according to the disclosed inventive concept in the treatment of disease by reducing or inhibiting inflammatory responses.Type: ApplicationFiled: May 14, 2021Publication date: November 18, 2021Applicant: ZIVO Bioscience, Inc.Inventors: Andrew A. Dahl, William P. Pfund, Amy E. Steffek
-
Patent number: 11065287Abstract: An algal biomass and supernatant derived from at least one species of algae exhibits anti-inflammatory and immune response modulating properties. Methods of reducing the symptoms of or treating a condition or disease in an animal, including bovine mastitis and Bovine Respiratory Disease Complex, and the pain and discomfort caused by osteoarthritis, injury or overexertion or muscle and connective tissue strains, comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or biologically active compound derived from the algae species, biomass or supernatant, or compositions thereof.Type: GrantFiled: February 16, 2016Date of Patent: July 20, 2021Assignee: ZIVO BIOSCIENCE, INC.Inventors: Andrew A. Dahl, Amy E. Steffek
-
Patent number: 10842179Abstract: A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual.Type: GrantFiled: November 7, 2016Date of Patent: November 24, 2020Assignee: Zivo Bioscience, Inc.Inventors: Smiti Vaid Gupta, Fazlul H. Sarkar, Andreea Geamanu, Andrew A. Dahl
-
Publication number: 20200330535Abstract: An algal biomass and supernatant derived from at least one species of algae exhibits the ability to maintain general health in humans and non-human animals and promote a healthy immune system in them. Food, feed and nutritional supplements comprising an algal biomass or supernatant derived from at least one species of algae are described. Methods of maintaining general health or promoting a healthy immune system in humans and non-human animals comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or homeopathic compound derived from the algae species, biomass or supernatant, or a composition thereof.Type: ApplicationFiled: February 15, 2017Publication date: October 22, 2020Applicant: Zivo Bioscience, Inc.Inventors: Andrew A. Dahl, Amy E. Steffek
-
Patent number: 10765732Abstract: The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-?, lactoferrin, IFN-?, IL-1?, serum amyloid-A (SAA), IL-6 and/or ?-defensin associated with infection or an immune response generally.Type: GrantFiled: February 12, 2019Date of Patent: September 8, 2020Assignee: ZIVO BIOSCIENCE, INC.Inventor: Andrew Dahl
-
Publication number: 20190175717Abstract: The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-?, lactoferrin, IFN-?, IL-1?, serum amyloid-A (SAA), IL-6 and/or ?-defensin associated with infection or an immune response generally.Type: ApplicationFiled: February 12, 2019Publication date: June 13, 2019Applicant: Zivo Bioscience, Inc.Inventor: Andrew Dahl
-
Patent number: 10232028Abstract: The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-?, IL-I ?, serum amyloid-A (SAA), IL-6 and/or ?-defensin associated with infection or an immune response generally.Type: GrantFiled: June 13, 2014Date of Patent: March 19, 2019Assignee: ZIVO BIOSCIENCE, INC.Inventor: Andrew Dahl